Popular Articles

Evaluating The ADHD Medication VYVANSE CII Demonstrated No Change In Pharmacokinetic Profile Of VYVANSE When Coadministered With Prilosec OTC 40 Mg
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters (maximum plasma concentration and area under curve) of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC. This study, which is the first to evaluate the pharmacokinetics of VYVANSE and ADDERALL XR taken alone and with Prilosec OTC 40 mg, was recently presented at the International Congress on Clinical Pharmacy, co-sponsored by the American College of Clinical Pharmacy (ACCP), in Orlando, FL.
generic viagra online
Most Parents Support Using Newborn Screening Data For Research
More than three-quarters of parents would be willing to permit the use of their children"s newborn screening samples for research purposes if their permission were obtained beforehand, a University of Michigan survey shows.
News of the day
American Physical Therapy Association Endorses The Ness L300™ Foot Drop System
The American Physical Therapy Association (APTA) announced its official product endorsement of the NESS L300 Foot Drop System, manufactured by Bioness Inc. of Valencia, CA, the first functional electrical stimulation (FES) foot drop system to be endorsed by APTA.
Oncology

Reducing Chronic Diseases Critical To Economic Recovery And Health Reform

An obese 70-year-old will spend approximately 20 percent more on health care over their lifetime - nearly $40,000 - than a peer of normal weight, according to the second annual Almanac of Chronic Disease, released today by the Partnership to Fight Chronic Disease (PFCD). The Almanac is a comprehensive re that outlines the critical role that preventing and reducing chronic diseases can have on health care reform, economic stability and the health of all Americans. Research highlights from the Almanac"s include: -- During 2007, the U.S. spent an estimated $1.7 trillion treating patients with one or more chronic conditions - the equivalent of 34 million annual salaries of $50,000. -- Since the mid-1980s, about two-thirds of the increase in spending on health care in the United States is linked to the rise in the prevalence of treated chronic diseases; about one-third is linked to the doubling of obesity rates. -- Chronic disease and treatment rates are higher in the United States than in other industrialized nations, and may add as much as $100 to $150 billion in treatment costs to U.S. health spending. "We need to address the sad reality that 75 cents of every dollar we spend on health care in our nation is to treat people suffering from a chronic disease," said PFCD National Chairperson Richard H. Carmona, M.D., M.P.H., FACS, 17th U.S. Surgeon General (2002-2006), President of the non-profit Canyon Ranch Institute. "The scientific evidence in the Almanac is clear. The health of our nation and our economy will only improve when we move from a "sick-care" system focused on treating chronic diseases to a true health care system devoted to prevention and wellness. The hundreds of PFCD partners who come from all sectors of American society are leading the way toward making the prevention of chronic diseases a national priority." At the press conference, Carmona, who is also Distinguished Professor of Public Health at the University of Arizona, was joined by Sen. Tom Harkin (D-Iowa), a senior member of the Committee on Health, Education, Labor and Pensions (HELP) who leads the Prevention and Public Health Working Group; Kenneth Thorpe, Ph.D., Executive Director of the Partnership to Fight Chronic Disease and Professor and Chair of the Department of Health Policy and Management at the Rollins School of Public Health at Emory University; and Virginia Wangerin, R.N., M.S.N., President of the Iowa Nurses Association. "We have heard millions of voices across the nation, by way of the President"s forums on health reform and other public events, calling for immediate action to resolve our economic challenges and improve health care in America," said Thorpe. "What the Almanac shows is that without reducing and better managing our country"s chronic disease rates and changing our delivery system from a treatment-oriented system to a prevention-oriented one, any short-term economic or health reform action will result in long-term failure." In addition to the hundreds of charts and statistics included in the Almanac, the publication also includes commentary from sponsoring organizations and excerpts from statements by national leaders in the areas of chronic disease, prevention and health care reform. "Unless we can realign our health care incentives to encourage preventive care and better disease management, our current course of "inaction" will soon cause irreparable damage to our nation"s economic viability and the strength of our greatest national asset: the health and wellbeing of the American people," Thorpe continued. "As we enter into a critical phase of the health reform discussion, lawmakers and the public should be aware of the desperate need to address this issue and the commitment of diverse stakeholders, like the PFCD, to see successful reform around chronic disease prevention and management." The Almanac was co-sponsored by several PFCD partner organizations: American Academy of Nursing; Canyon Ranch Institute; DMAA: The Care Continuum Alliance; National Association of Chronic Disease Directors (NACDD); National Association of Public Hospitals and Health Systems; Pharmaceutical Research and Manufacturers of America (PhRMA); U.S. Chamber of Commerce; and YMCA of the USA. About the Partnership to Fight Chronic Disease: The Partnership to Fight Chronic Disease (PFCD) is a national coalition of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs in the U.S.: chronic disease. Partnership to Fight Chronic Disease


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):